Healthcare / BiotechnologyHKSE
$0.71
-0.02 (-2.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 21%
FCF escenarios
weak_data · normalized FCF $154.1M · quality 38.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.8B
P/E
N/A
•EV/EBITDA
26.0x
↑ROE
-4.9%
↓Gross Margin
29.1%
↓Debt/Equity
1.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.8%
FCF CAGR
—
FCF margin
-1.1%
FCF / Net income
0.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.41B · net income $-186.8M · FCF $-61.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.41B | $5.41B | $5.52B | $5.32B | $5.28B |
| Net Income | $-186.8M | $-186.8M | $-126.6M | $17.3M | $132.0M |
| EBITDA | $494.2M | $494.2M | $490.9M | $624.8M | $598.9M |
| EPS | -0.02 | -0.02 | -0.01 | 0.00 | 0.01 |
| Gross Margin | 29.1% | 29.1% | 30.6% | 30.8% | 30.8% |
| Operating Margin | -2.4% | -2.4% | 1.4% | 4.2% | 4.6% |
| Net Margin | -3.5% | -3.5% | -2.3% | 0.3% | 2.5% |
| Balance Sheet | |||||
| Debt/Equity | 1.75 | 1.75 | 1.74 | 1.42 | 1.43 |
| Current Ratio | 0.87 | 0.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-61.0M | $-61.0M | $154.1M | $222.4M | $146.7M |
| Returns | |||||
| ROE | -4.9% | -4.9% | -3.6% | 0.4% | 3.2% |
| Valuation | |||||
| P/E | — | — | — | 344.44 | 59.85 |
| EV/EBITDA | 25.99 | 25.99 | 19.23 | 17.97 | 21.93 |
| P/B | 1.81 | 1.81 | 1.11 | 1.42 | 1.90 |
| Growth & Yield | |||||
| Revenue Growth | -2.0% | -2.0% | 3.8% | 0.9% | — |
| EPS Growth | -47.0% | -47.0% | -833.3% | -86.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.02
Residual
-13.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.